Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q13702

UPID:
RAPSN_HUMAN

ALTERNATIVE NAMES:
43 kDa postsynaptic protein; Acetylcholine receptor-associated 43 kDa protein; RING finger protein 205

ALTERNATIVE UPACC:
Q13702; Q8TDF3; Q9BTD9

BACKGROUND:
The 43 kDa receptor-associated protein of the synapse is crucial for the proper functioning of neuromuscular junctions, ensuring the effective clustering of nAChRs. Known alternatively as Acetylcholine receptor-associated 43 kDa protein and RING finger protein 205, it potentially connects the receptor with the postsynaptic cytoskeleton.

THERAPEUTIC SIGNIFICANCE:
Its association with diseases such as congenital myasthenic syndrome 11 and fetal akinesia deformation sequence 2 highlights the protein's therapeutic potential. Exploring the role of this protein could open doors to potential therapeutic strategies for these and related neuromuscular disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.